ResearchBlogShop Mitopure

First Human Clinical Trial On Anti-Aging Compound Mitopure

The first human clinical trial results on the anti-aging compound Mitopure, a proprietary, highly pure form of Urolithin A

Man in a climbing harness

June 14, 2019

3 min read

Amazentis, an innovative life sciences company pioneering scientific breakthroughs in nutrition to manage health conditions linked to aging, announced today a collaborative publication in Nature Metabolism with scientists at the École Polytechnique Fédérale de Lausanne (EPFL) and the Swiss Institute of Bioinformatics (SIB) demonstrating the Company’s lead product, Mitopure, is safe, bioavailable and improves mitochondrial and cellular health in humans.

Mitopure was orally administered in both single and multiple (4 weeks) daily dosing to 60 healthy elderly subjects in a double-blind, randomized, placebo-controlled study. The trial showed that regular Mitopure dosing during 4 weeks is safe, bioavailable and effective in improving mitochondrial health through upregulation of mitochondrial gene expression localized to the skeletal muscle and by improving systemic plasma acylcarnitines associated with cellular and mitochondrial function.

Roger Fielding, PhD, Professor of Medicine and Nutrition and Associate Director of the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, commented, “There are currently no effective solutions to treat age-related decline in muscle function other than months of exercise. This is an important first clinical validation that shows Urolithin A could be a promising solution for the management of healthy muscle function during aging.”

“Mitochondrial and cellular health declines with age, making these results a pivotal milestone as we explore the full breadth of benefits Urolithin A offers for managing human health throughout the aging process,” stated Patrick Aebischer, MD, co-author on the article, EPFL President Emeritus, and Chairman and Co-founder of Amazentis.

“This positive clinical translation of Urolithin A shows its potential to play an important role in advanced nutritional approaches to improve mitochondrial health through mitophagy and biogenesis, and, as a result, cellular health in humans,” added Johan Auwerx, MD, PhD, co-author and Professor at the EPFL.

Nestlé Health Science recently announced a global partnership with Amazentis to develop products containing Mitopure to pursue opportunities in consumer healthcare and medical nutrition.

Chris Rinsch, PhD, lead author, Co-founder and CEO of Amazentis, said, “The rigorous clinical science being published in Nature Metabolism is a critical step towards translating our breakthrough scientific discoveries in nutrition into clinically validated consumer health products that address today’s unmet needs for healthy aging.”

The results are being reported in the current issue of Nature Metabolism in an article titled, “The mitophagy activator Urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans” (doi: 10.1038/s42255-019-0073-4).


Amazentis Editorial Staff

Related articles

Keep up with the science of Urolithin A

Get updates straight to your inbox

Privacy policy